Biomarkers for Detection of Dysplastic Barrett’s Oesophagus
Research type
Research Study
Full title
Biomarkers for Detection of Dysplastic Barrett’s Oesophagus in Retrospective Capsule Sponge Samples (DysplasiaBAR)
IRAS ID
334861
Contact name
Samantha Roberts
Contact email
Sponsor organisation
Cyted Health Ltd
Duration of Study in the UK
3 years, 0 months, 1 days
Research summary
Oesophageal cancer is a disease with a very poor survival rate with fewer than 1 in 5 (<20%) patients surviving five years after diagnosis. This is primarily due to late stage diagnosis, resulting in poor response to available treatments.
However, there is a clear opportunity for early diagnosis in the most common subtype of the disease in Western countries (Oesophageal adenocarcinoma) with a pre-malignant condition called Barrett’s oesophagus. Patients who are known to have Barrett’s have an increased risk of developing cancer, though the risk is still relatively low with 1 in 300 patients with Barrett’s diagnosed with a cancer per year.
A non-endoscopic cell collection (i.e. EndoSign) and biomarker test for Barrett’s diagnosis and cancer risk has been offered by Cyted Ltd since 2020 as a minimally-invasive alternative to endoscopy for Barrett’s surveillance. Cyted is currently developing new molecular biomarkers for detection of Barrett’s and dysplasia/early cancer. In order to validate the selected biomarkers a cohort of patients known to be high risk due to previous capsule sponge testing who have had (or will have) a follow-up endoscopic biopsy will be asked to share their endoscopic pathology and prior diagnostic sample for analysis.REC name
East Midlands - Derby Research Ethics Committee
REC reference
24/EM/0147
Date of REC Opinion
3 Jul 2024
REC opinion
Further Information Favourable Opinion